CommercialCoverageLow impact
Kebilidi (eladocagene exuparvovec-tneq)
Blue Cross & Blue Shield of Mississippi·MS · Neurology, Pediatrics, Endocrinology·Medical Policy
Effective date
Sep 1, 2025
We identified it
Jun 20, 2026
Summary
BCBSMS has added a new policy classifying Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, as investigational and not covered. All services related to this medication will be considered not medically necessary without prior authorization approval.
Action Required
By September 1, 2025: Billing team must update system to flag Kebilidi (eladocagene exuparvovec-tneq) as investigational and requiring prior authorization through BCBSMS PA review process. Use HCPCS code J3590 for billing. Notify providers that this gene therapy is considered investigational and claims will be denied without PA approval.